Lonza and Junshi Biosciences expand biologics manufacturing collaboration
![](/46/pdcnewsitem/11/17/45/HLN00CPO_Lonza_770x400.jpg)
The antibody-based products will be expressed using Lonza's GS Xceed Gene Expression System
Global contract development and manufacturing organisation (CDMO) Lonza said it has expanded its collaboration deal with Junshi Biosciences, whereby the global CDMO will provide its network and local operation capabilities to help the innovative Chinese pharmaceutical company accelerate its biologics development and manufacturing.
As part of the agreement, Lonza will provide cell line construction and development, the supply of cell culture media and reagents, process development, and GMP manufacturing.
The collaboration will also extend to development and manufacturing support for Junshi Biosciences' current and future antibody-based product pipeline, which includes a new antibody candidate that will be manufactured at Lonza's first mammalian facility in Guangzhou that has been fully operational since Q1 2021.
The main production platform will use Lonza's GS Xceed Expression System, which covers various techniques and commercialised processes such as host cells, expression vectors and optimized culture media.
In addition, Lonza will leverage its manufacturing network for biological products spanning three continents, as well as its globally unified quality control standards to help Junshi Biosciences accelerate its venture into international markets and help bring innovation from China to the world.
Using Lonza's GS Xceed Expression System, Junshi Biosciences has already successfully launched China's first local antibody targeting PD-1 (Toripalimab Injection, TUOYI) in 2018 and took its neutralizing antibody drug JS016 (etesevimab) for COVID-19 to clinical trial stage in 2020.
![Lonza](https://www.cphi-online.com/c248548th_S-comp248548.jpg)
Related News
-
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance